Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
KALA BIO, Inc.: Filed Certificate of Designations for Series G Convertible Non-Redeemable Preferred Stock (effective 2024-03-25).
- Change
- charter amendment
- Effective
- 2024-03-25
Exact text from the filing
On March 25, 2024 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series G Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series G Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
KALA BIO, Inc. entered into Securities Purchase Agreement with certain institutional investors named therein valued at aggregate gross proceeds of approximately $8.6 million (effective 2024-03-25).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors named therein
- Value
- aggregate gross proceeds of approximately $8.6 million
- Effective
- 2024-03-25
Exact text from the filing
On March 25, 2024, KALA BIO, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement priced at-the-market under Nasdaq rules, shares (the “Preferred Shares”) of Series G Convertible Non-Redeemable Preferred Stock, par value $0.001 per share, of the Company (the “Series G Preferred Stock”), for aggregate gross proceeds of approximately $8.6 million (the “Private Placement”).
View on SEC.gov